United Kingdom

People: Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

23 Aug 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Ives, Jeffrey 

Dr. Jeffrey L. Ives, Ph.D., serves as an Independent Director of the Company. From 2008 until 2013, Dr. Ives currently is a Venture Partner at New Leaf Venture Partners, healthcare technology venture firm, and a Principal at NeuroPharma Advisors, LLC., an advisory group focused on companies developing therapeutics for the CNS. Dr. Ives is also currently a director at private pharmaceutical and biotechnology companies, Astrocyte Pharmaceuticals Inc., Acumen Pharmaceuticals, Inc., Pinteon Therapeutics Inc. and Orthogonal Neurosciences, private. Previously, Dr. Ives served as the Chief Executive Officer of Satori Pharmaceuticals, Inc., a neurodegenerative disease company focused on discovery and development of breakthrough therapies for the treatment and prevention of Alzheimer’s disease from 2008 until 2013. Prior to Satori, Dr. Ives led the CNS, pain and oncology research teams at Pfizer for over two decades and, from 2001 to 2007, he served as a Senior Vice President leading the global Pharmacokinetics, Dynamics and Metabolism organization. Dr. Ives received his doctorate and master degrees from Yale University and received his bachelor of arts degree from Colgate University. His extensive experience leading research and drug development provides him with the qualifications to serve on the Board.

Basic Compensation

Total Annual Compensation, USD 57,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 224,261
Fiscal Year Total, USD 281,261

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Derek Chalmers


Mani Mohindru


Frederique Menzaghi


Scott Terrillion


Joana Goncalves


Martin Vogelbaum

As Of  31 Dec 2018